Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum CECT 7481 + lactobacillus brevis CECT 7480
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Buccal
01
Overview
Lactobacillus plantarum CECT 7481 + Lactobacillus brevis CECT 7480 is a probiotic combination consisting of two specific bacterial strains isolated from the human oral microbiota. Developed by AB-Biotics, this combination is designed to promote oral health by colonizing the oral cavity and exhibiting antagonistic activity against key periodontal pathogens, including Porphyromonas gingivalis, Treponema denticola, and Fusobacterium nucleatum. The strains are characterized by their low acidogenic activity, which helps preserve tooth enamel while reducing dental plaque formation. It is primarily indicated for the prevention and treatment of oral disorders such as gingivitis, halitosis, and candidiasis, and is commercially available in formulations like lozenges and chewing gums under brand names such as AB-Dentalac and Jarro-Dophilus Oral Probiotic.
- Brand names
- AB-DentalacJarro-Dophilus Oral Probiotic
- Other names
- Lactobacillus plantarum CECT 7481Lactobacillus brevis CECT 7480L. plantarum CECT 7481 + L. brevis CECT 7480
Beyond the preview
Go deeper on lactobacillus plantarum CECT 7481 + lactobacillus brevis CECT 7480.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum CECT 7481 + lactobacillus brevis CECT 7480.